Skip to content
SpinProtide US

Providing Stem Cells During Pregnancy to Infants with Neural Tube Defect Enhances Quality of Life, Trial Finds

A groundbreaking clinical study has discovered that providing pluripotent cells to developing infants suffering from spina bifida while undergoing fetal surgery could constitute a "major milestone" in managing prenatal disorders.

Trial Details and Safety

The US-based trial involved six fetuses with the 'open' form of spina bifida. Medical teams placed placenta-derived mesenchymal stem cells to the surface of the infant's spine as part of the surgical correction.

Critically, the regenerative treatment was found to be safe. The study team reported that the treatment did not lead to tumors, interfere with wound healing, or prevent the reversal of co-occurring hindbrain herniation.

Positive Developments

Post-birth MRI scans confirmed a successful correction of Chiari malformation in each of the babies. This neurological improvement is a key indicator for improved motor skills and quality of life.

"In the event it allows additional babies to achieve ambulation who wouldn't have, then it would become the new treatment paradigm," noted the study director. "The outcomes appear profoundly encouraging and create a pathway toward a variety of prospective new treatments."

Broader Impact and Encouragement

Experts not involved in the trial indicated that additional validation of these apparent benefits could announce a "new era" in prenatal intervention. The possibility of ameliorating neural deficits seen in utero is considered a transformative goal.

Notably important would be better management of bladder and bowel function, which are frequent complications for people affected by this defect.

Future Directions

Although this preliminary study involved a limited number of patients, its safety demonstration and positive signals provide a strong foundation for larger, more comprehensive studies. The addition of cellular treatment with established fetal surgery techniques holds considerable promise for transforming outcomes for infants diagnosed prenatally with myelomeningocele.

The writer

Chris Mcdonald

A biochemist with over 15 years of experience in protein engineering and molecular biology research.

SpinProtide US

Type to search articles.